Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10490MR)

This product GTTS-WQ10490MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10490MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6097MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ169MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ9189MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ9817MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ12542MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ5144MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ10810MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ3356MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW